<DOC>
	<DOCNO>NCT01816490</DOCNO>
	<brief_summary>Chronic hepatitis C virus ( HCV ) major cause morbidity mortality worldwide estimate number 180 million infected patient . Until 2012 current standard care ( SOC ) treatment patient chronic hepatitis C 24 72 week therapy pegylated interferon- ribavirin ( PR ) . In 2012 , protease-inhibitors ( PI 's ) telaprevir boceprevir first directly act HCV drug approve local Swiss authority hepatitis C mono-infected HCV-HIV-co-infected individual . However , therapy success strongly limit null-responders ( NR ) previous PR . Treatment HCV-HIV co-infected individual new PI 's accompanied additional challenge ( e.g . drug-drug interaction , toxicity , high pill burden ) . Patients advanced fibrosis high risk decompensated liver disease hepatocellular carcinoma ( HCC ) prompt initiation treatment strongly recommend . Recently , data mono-infected patient show , prior non responder 12 week course triple therapy ( TT ) telaprevir PR follow another 24 week PR result sustain virologic response ( SVR ) 29 % . In HCV-HIV co-infected non-responders unfavourable precondition ( e.g . HCV-genotype 1 , interleukin 28 B non-CC genotype , advance liver fibrosis , high baseline HCV viral load ) SVR TT even expect low . These patient urgently need additional therapeutic option goal eradicate HCV order prevent fibrosis progression reduce morbidity mortality . A promising substance field drug target HCV replication silibinin . Silibinin main component silymarin , extract milk thistle Silybum marianum . Intravenous silibinin ( iSIL ) target multiple step virus life cycle exhibit anti-oxidant , anti-inflammatory , anti-viral immunomodulatory property . iSIL inhibits HCV NS5B polymerase activity directly interfere bind RNA enzyme . In addition , iSIL appear block virus entry , virus transmission virus secretion.In 2008 Ferenci et al . first time report substantial clinical antiviral-effect intravenous silibinin ( iSIL ) HCV PR non-responders . The administration 20mg/kg iSIL 20 patient lead highly significant decrease viral load . We intend investigate effect tolerability iSIL HIV-HCV co-infected individual advance liver fibrosis previous non- partial response SOC . All include study-subjects receive lead-in therapy iSIL dosage 20mg/kg/day ( express silibinin concentration ) day 14 day . At end THISTLE study , i.e . day completion 14-day iSIL administration ( day 15 ) , patient consider eligibility receive standard care . We assume decline HCV viral load would substantially improve chance SVR reduction viral load increase efficacy PR reduce odds drug resistance HCV-specific protease inhibitor . - Trial medicinal product</brief_summary>
	<brief_title>THISTLE - The HIV-HCV Silibinin Trial</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Silybin</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>Inclusion criterion : Age great equal 18 year HIVHCV coinfection HCV Genotype 1 infection At least one liver biopsy since diagnosis HCVinfection Fibrosis score METAVIR = 2 documented biopsy OR stiffness great equal 7.0 kPa document fibroscan previous 12 month . Documented previous nullresponse partialresponse SOC Exclusion criterion : Contraindications study drug study , e.g . know hypersensitivity allergy ingredient study drug Patients need ART HIV virological failure ( = 400 copies/ml ) last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>